Best Momentum Stocks to Buy for December 30th

Photo of author

By Ronald Tech

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, December 30th:

CoreCard Corporation CCRD: This technology solutions and processing services company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7% over the last 60 days.

CoreCard Corporation Price and Consensus

CoreCard Corporation Price and Consensus

CoreCard Corporation price-consensus-chart | CoreCard Corporation Quote

CoreCard’s shares gained 44.9% over the last three months compared with the S&P 500’s advance of 5.3%. The company possesses a Momentum Score  of A.

CoreCard Corporation Price

CoreCard Corporation Price

CoreCard Corporation price | CoreCard Corporation Quote

Entrada Therapeutics, Inc. TRDA: This clinical-stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 64.7% over the last 60 days.

Entrada Therapeutics, Inc. Price and Consensus

Entrada Therapeutics, Inc. Price and Consensus

Entrada Therapeutics, Inc. price-consensus-chart | Entrada Therapeutics, Inc. Quote

Entrada’s shares gained 8.8% over the last three months compared with the S&P 500’s advance of 5.3%. The company possesses a Momentum Score of A.

Entrada Therapeutics, Inc. Price

Entrada Therapeutics, Inc. Price

Entrada Therapeutics, Inc. price | Entrada Therapeutics, Inc. Quote

NRx Pharmaceuticals, Inc. NRXP: This clinical-stage biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 46.2% over the last 60 days.

NRx Pharmaceuticals, Inc. Price and Consensus

NRx Pharmaceuticals, Inc. Price and Consensus

NRx Pharmaceuticals, Inc. price-consensus-chart | NRx Pharmaceuticals, Inc. Quote

NRx’s shares gained 11.8% over the past month compared with the S&P 500’s decline of 0.7%. The company possesses a Momentum Score of A.

NRx Pharmaceuticals, Inc. Price

NRx Pharmaceuticals, Inc. Price

NRx Pharmaceuticals, Inc. price | NRx Pharmaceuticals, Inc. Quote

See also  S&P 500: Potential for 6,000 This Year and Forecasting a Correction in 2025 S&P 500: Potential for 6,000 This Year and Forecasting a Correction in 2025

 

See the full list of top ranked stocks here

 

Learn more about the Momentum score and how it is calculated here.

Zacks Naming Top 10 Stocks for 2025

Want to be tipped off early to our 10 top picks for the entirety of 2025?

History suggests their performance could be sensational.

From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2025. Don’t miss your chance to get in on these stocks when they’re released on January 2.

Be First to New Top 10 Stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report

NRx Pharmaceuticals, Inc. (NRXP) : Free Stock Analysis Report

Entrada Therapeutics, Inc. (TRDA) : Free Stock Analysis Report

CoreCard Corporation (CCRD) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research